Phase 1 trial of zolbetuximab in Japanese patients with <scp>CLDN18</scp> .2+ gastric or gastroesophageal junction adenocarcinoma

Zolbetuximab is a chimeric monoclonal antibody that targets claudin-18.2, a candidate biomarker in patients with advanced gastric/gastroesophageal cancer. This nonrandomized phase 1 study (NCT03528629) enrolled previously treated Japanese patients with claudin-18.2-positive locally advanced/metastatic gastric/gastroesophageal cancer in 2 parts: Safety (Arms A and B, n=3 each) and Expansion (n=12). Patients received zolbetuximab i.v. 800 mg/m